Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study

Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines

“…Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, abbreviated as dFdCyd) is a nucleoside analog that is clinically used to treat patients with different types of cancer such as pancreatic, non-small cell lung and metastatic breast cancer (Bernhard et al, 2008;Burris et al, 1997;Chew et al, 2009;Crino et al, 1998;Yardley et al, 2008;Zatloukal et al, 1998). In vitro studies have demonstrated that dFdCyd can enhance cell killing by ionizing radiation (termed "radiosensitization") in colorectal, breast, pancreatic, ovarian, and non-small cell lung cancer cell lines McGinn et al, 1996;Robinson and Shewach, 2001;Robinson et al, 2003;Shewach et al, 1994).…”

ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy

“…Combinationchemotherapy with cisplatin and gemcitabine is extensively studied in NSCLC patients. Gemcitabine (2 ,2 -difluoro-2 -deoxycytidine) is a nucleoside analogue which has shown antitumour activity in NSCLC as a single agent [3][4][5][6][7][8][9][10]. Synergistic cytotoxicity between cisplatin and gemcitabine has also been demonstrated in vitro [11,12].…”

Tolerability of Gemcitabine and Carboplatin Doublet Therapy in Cats with Carcinomas

“…Gemcitabine (2′,2′‐difluorodeoxycytidine) is a pyrimidine nucleoside analogue that resembles deoxycytidine 1 and has substantial single‐agent clinical activity against solid tumors and hematologic neoplasms in humans 2–5 . The mechanism of action involves incorporation into strands of replicating DNA, in competition with deoxycytidine triphosphate, leading to “masked‐chain termination” and inhibition of DNA replication and repair 1,6 .…”